caa a22 4500 465736882 CHVBK 20180323111757.0 cr unu---uuuuu 170327e19900901xx s 000 0 eng 10.1007/BF02245748 doi (NATIONALLICENCE)springer-10.1007/BF02245748 Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients [Elektronische Daten] [J. Den Boer, D. Ravelli, J. Huisman, J. Ohrvik, W. Verhoeven, H. Westenberg] In the present 6-week double-blind, randomised, multicentre study, the atypical neuroleptic remoxipride was compared to haloperidol in acute schizophrenic patients (DSM-III). Seventy-one patients entered the study, 36 in the remoxipride group and 35 in the haloperidol group. There were ten early withdrawals, four in the remoxipride group and six patients in the haloperidol group. The Present State Examination (PSE) profile revealed a similar reduction in the symptom clusters of psychosis in both treatment groups. Forty-seven per cent of the patients in the remoxipride group and 34% of the patients in the haloperidol group showed clinically relevant improvement (reduction of BPRS total score ≥ 50%). All extrapyramidal symptoms except "glabella tap” occurred significantly less frequently in the remoxipride group as compared to the haloperidol group. Substantially lower incidences of EPS were found by active questioning in the remoxipride group compared to the haloperidol group. In addition, considerably lower incidences were observed in the remoxipride group with respect to drowsiness/somnolence, tiredness/fatigue and concentrating difficulty. At the end of treatment 66% of the patients in the haloperidol group and 22% in the remoxipride group were using anticholinergics. No consistent changes were found in the mean plasma HVA level in either treatment group. In responders (reduction of BPRS total score ≥ 50%) lower baseline HVA levels were observed in both treatment groups. This study indicates that the newly developed neuroleptic remoxipride is an effective antipsychotic compound, which is clinically safe and well tolerated. In particular, few EPS were induced by remoxipride, as compared to haloperidol. Springer-Verlag, 1990 Atypical neuroleptics nationallicence Remoxipride nationallicence Haloperidol nationallicence Schizophrenia nationallicence Homovanillic acid nationallicence Den Boer J. Department of Biological Psychiatry, University Hospital, P.O. Box 85500, NL-3508 GA, Utrecht, The Netherlands aut Ravelli D. Psychiatric Hospital "Zon & Schild”, Utrechtseweg 266, NL-3818 EW, Amersfoort, The Netherlands aut Huisman J. Psychiatric Hospital "Zon & Schild”, Utrechtseweg 266, NL-3818 EW, Amersfoort, The Netherlands aut Ohrvik J. Department of Statistics, University of Stockholm, S-106 91, Stockholm, Sweden aut Verhoeven W. Department of Biological Psychiatry, University Hospital, P.O. Box 85500, NL-3508 GA, Utrecht, The Netherlands aut Westenberg H. Department of Biological Psychiatry, University Hospital, P.O. Box 85500, NL-3508 GA, Utrecht, The Netherlands aut Psychopharmacology Springer-Verlag 102/1(1990-09-01), 76-84 0033-3158 102:1<76 1990 102 213 https://doi.org/10.1007/BF02245748 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245748 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Den Boer J. Department of Biological Psychiatry, University Hospital, P.O. Box 85500, NL-3508 GA, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- Ravelli D. Psychiatric Hospital "Zon & Schild”, Utrechtseweg 266, NL-3818 EW, Amersfoort, The Netherlands aut NATIONALLICENCE 700 1- Huisman J. Psychiatric Hospital "Zon & Schild”, Utrechtseweg 266, NL-3818 EW, Amersfoort, The Netherlands aut NATIONALLICENCE 700 1- Ohrvik J. Department of Statistics, University of Stockholm, S-106 91, Stockholm, Sweden aut NATIONALLICENCE 700 1- Verhoeven W. Department of Biological Psychiatry, University Hospital, P.O. Box 85500, NL-3508 GA, Utrecht, The Netherlands aut NATIONALLICENCE 700 1- Westenberg H. Department of Biological Psychiatry, University Hospital, P.O. Box 85500, NL-3508 GA, Utrecht, The Netherlands aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 102/1(1990-09-01), 76-84 0033-3158 102:1<76 1990 102 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer